A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor
Open accessThe DOI matches its Crossref record; 95 of the 95 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The neurochemical and biological effects of antidepressant medications have become better defined over the last decade. When the anti-depressant bupropion was introduced in the United States in 1989, the specific pharmacologic basis of its clinical effects was uncertain. Research conducted over the past decade has significantly advanced the understanding of the neuropharmacology of bupropion and has demonstrated a novel mechanism of antidepressant activity. This article discusses the mechanism of action of bupropion and relates the drug's neuropharmacologic effects to its clinical efficacy and tolerability profiles. DATA SOURCES: Data were obtained via the MEDLINE database in an English-language search spanning the period 1965 to May 2002 and using the search terms bupropion, bupropion SR, and antidepressants, as well as from the manufacturer's bupropion databases. CONCLUSIONS: The preclinical and clinical data show that bupropion acts via dual inhibition of norepinephrine and dopamine reuptake and is devoid of clinically significant serotonergic effects or direct effects on postsynaptic receptors. Dual norepinephrine and dopamine reuptake inhibition is associated with a unique clinical profile. Bupropion has demonstrated efficacy comparable to that of other antidepressants. However, because bupropion is a selective norepinephrine and dopamine reuptake inhibitor with no serotonergic activity, common antidepressant-associated side effects, such as sexual dysfunction, weight gain, and sedation, are not associated with bupropion therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Bupropion is a second-generation AD that acts as a selective inhibitor of catecholamines' (noradrenaline and dopamine) reuptake, devoid of any serotonergic; antihistamine; or anticholinergic properties (Stahl et al., 2004).”
From Is There a Potential of Misuse for Venlafaxine and Bupropion? (2018) · cites this paper as Stahl et al., 2004
In the citing paper
“Inhibition of catecholamine reuptake is one of bupropion’s mechanisms of action [215].”
From Mechanistic insights into nicotine withdrawal (2011) · cites this paper as [215]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Selective serotonin reuptake inhibitors (SSRIs) versus other antidepressants for depression
Geddes, J. R., Freemantle, N., Mason, J. M., Eccles, M., & Boynton, J. R. (1999) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001851 · Cited by 125
RetractedGoodman & Gilman's The Pharmacological Basis of Therapeutics
Brunton, L. L. (1985) · Cited by 7,321
Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants
Santarelli, L., Saxe, M., Gross, C., Surget, A., Battaglia, F., Dulawa, S., Weisstaub, N., Lee, J., Duman, R., Arancio, O., et al. (2003) · Science · doi:10.1126/science.1083328 · Cited by 4,321
The cellular neurobiology of depression
Manji, H. K., Drevets, W. C., & Charney, D. S. (2001) · Nature Medicine · doi:10.1038/87865 · Cited by 1,182 · cited 1×
“cause depression and modulate responses to antidepressants.(14,16,19) Several observations support an “upstream””
BackgroundUntreated Depression and Hippocampal Volume Loss
Sheline, Y. I., Gado, M. H., & Kraemer, H. C. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.8.1516 · Cited by 1,180 · cited 1×
“Antidepressants may thus play a neuroprotective role, a possibility supported by observations that hippocampal neurogenesis may be required for the behavior effects of antidepressants in mice(23) and that progressive loss of hippocampal volume occurs during chronically untreated depression in humans.(24,25)”
BackgroundPharmacological profile of antidepressants and related compounds at human monoamine transporters
Tatsumi, M., Groshan, K., Blakely, R. D., & Richelson, E. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01393-9 · Cited by 939 · cited 1×
“For example, antidepressants differ by more than 1000fold in potency at inhibiting monoamine reuptake, yet their efficacies are comparable and seemingly unrelated to potency.(21) Third, although all antidepressants enhance monoaminergic neurotransmission, they do so via disparate mechanisms, consistent with the possib…”
Background(2000) · PubMed · Cited by 685
Bupropion: a review of its mechanism of antidepressant activity.
Ascher, J. A., Cole, J. O., Colin, J. N., Feighner, J. P., Ferris, R. M., Fibiger, H. C., Golden, R. N., Martin, P., Potter, W. Z., & Richelson, E. (1995) · PubMed · Cited by 680
Prevalence of Sexual Dysfunction Among Newer Antidepressants
Clayton, A. H., Pradko, J. F., Croft, H. A., Montano, C. B., Leadbetter, R. A., Bolden-Watson, C., Bass, K. I., Donahue, R. M. J., Jamerson, B. D., & Metz, A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0414 · Cited by 542
Self-citation
Research works printed but not linked: 27
- Ferris RM, Cooper BR. Mechanism of antidepressant activity of bupropion. J Clin Psychiatry Monograph. 1993;11(1):2–14. [PubMed] [Google Scholar]
- GlaxoSmithKline. data on file, Research Triangle Park, NC. 2002. [Google Scholar]
- Stahl SM. Essential Psychopharmacology. 2nd ed. New York, NY: Cambridge University Press. 2000 [Google Scholar]
- Remeron [package, insert]. West Orange, NJ: Organon. 2002. [Google Scholar]
- Serzone [package, insert]. Princeton, NJ: Bristol-Myers Squibb Company. 2002. [Google Scholar]
- Holden C. ed. Random samples: don't go off the Prozac. Science. 2003 301:760–761. [Google Scholar]
- Szabó Z, Àrgyelán M, and Kanyó B. et al. The effect of bupropion on the activity of dopamine transporter in depression: preliminary results [abstract]. Eur Neuropsychopharmacol. 2003 13(suppl 4):S210. [Google Scholar]
- American Psychiatric Association. Major Depressive Disorder: A Patient and Family Guide, 2001. Available at: www.psych.org. Accessed June 7, 2001. [Google Scholar]
- Geddes JR, Freemantle N, and Mason J. et al. SSRIs versus other anti-depressants for depressive disorder. Cochrane Database Syst Rev 2000(2):CD001851. [DOI] [PubMed] [Google Scholar]
- Thase ME, Haight BR, and Richard NE. et al. Remission rates following therapy with bupropion or SSRIs. Presented at the 156th annual meeting of the American Psychiatric Association. 17–22May2003 San Francisco, Calif. [Google Scholar]
- Boyer WF, Feighner JP. The combined use of fluoxetine and bupropion [poster]. Presented at the 146th annual meeting of the American Psychiatric Association. 22–27May1993 San Francisco, Calif. [Google Scholar]
- Ramasubbu R. Treatment of resistant depression by adding noradrenergic agents to lithium augmentation of SSRIs. Ann Pharmacother. 2002;36:634–640. doi: 10.1345/aph.10408. [DOI] [PubMed] [Google Scholar] · doi:10.1345/aph.10408 · Paper page
- Spier SA. Use of bupropion with SRIs and venlafaxine. Depress Anxiety. 1998;7:73–75. [PubMed] [Google Scholar]
- Yeghiya M, Danielyan A, and Khachatur G. et al. Augmentation of SSRIs with bupropion in treatment resistant depression in adolescents [abstract]. Presented at the 156th annual meeting of the American Psychiatric Association. 17–22May2003 San Francisco, Calif. [Google Scholar]
- DeBattista C, Solvason HB, and Fleming S. et al. A placebo-controlled, double-blind study of bupropion SR in the treatment of SSRI-induced sexual dysfunction [poster]. Presented at the 154th annual meeting of the American Psychiatric Association. 5–10May2001 New Orleans, La. [DOI] [PubMed] [Google Scholar]
- Solvason HB, DeBattista C, and Kendrick E. et al. Bupropion SR in the treatment of SSRI-induced sexual dysfunction [poster]. Presented at the 40th annual meeting of the New Clinical Drug Evaluation Unit Program (NCDEU). May 30–June 2, 2000 Boca Raton, Fla. [Google Scholar]
- Johnston JA, Schmidt G, and Ascher J. et al. Pharmacokinetic optimization of bupropion SR for smoking cessation. Drugs. 2002 62(suppl 2):11–24. [DOI] [PubMed] [Google Scholar]
- Hudziak JJ, Wilens TE, and Rosenthal NE. et al. The efficacy of extended-release bupropion in adult ADHD [poster]. Presented at the 42nd annual meeting of the American College of Neuropsychopharmacology. 7–11December2003 San Juan, Puerto Rico. [Google Scholar]
- Rosenthal NE, Modell JG, and Harriett A. et al. Wellbutrin XL for the prevention of seasonal depressive episodes [poster]. Presented at the 42nd annual meeting of the American College of Neuropsychopharmacology. 7–11December2003 San Juan, Puerto Rico. [Google Scholar]
- Clayton AH, West SG. The effects of antidepressants on human sexuality. Primary Psychiatry. 2003;10:62–70. [Google Scholar]
- Westlund R, Haight BR, and Harriett A. et al. Effect on body weight of bupropion in patients with major depression [poster]. Presented at the 16th Annual US Psychiatric & Mental Health Congress. 6–9November2003 Orlando, Fla. [Google Scholar]
- Celexa [package, insert]. St Louis, Mo: Forest Laboratories. 2002. [Google Scholar]
- Prozac [package, insert]. Indianapolis, Ind: Eli Lilly and Company. 2002. [Google Scholar]
- Paxil [package, insert]. Research Triangle Park, NC: GlaxoSmithKline. 2002. [Google Scholar]
- Zoloft [package, insert]. New York, NY: Pfizer Inc. 2002. [Google Scholar]
- Effexor [package, insert]. Philadelphia, Pa: Wyeth. 2002. [Google Scholar]
- Wellbutrin [package, insert]. Research Triangle Park, NC: GlaxoSmithKline. 2002. [Google Scholar]
Cited by
Reconsidering anhedonia in depression: Lessons from translational neuroscience
Treadway, M. T., & Zald, D. H. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.06.006 · Cited by 1,579
“It is well established that bupropion has little direct effect on 5HT function (Stahl et al., 2004).”
BackgroundMalhi, G. S., Bassett, D., Boyce, P., Bryant, R., Fitzgerald, P. B., Fritz, K., Hopwood, M., Lyndon, B., Mulder, R., Murray, G., et al. (2015) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867415617657 · Cited by 842
“However, if the patient was nonresponsive to the initial SSRI, switching out of class to a SNRI (i.e., venlafaxine), NDRI or TCA, is recommended (Ruhé et al., 2006b; Rush et al., 2006).”
BackgroundA brief history of the development of antidepressant drugs: From monoamines to glutamate.
Hillhouse, T. M., & Porter, J. H. (2015) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0038550 · Cited by 605
“Bupropion IR requires three daily doses; thus, to reduce daily dosing regimens, the sustained-release (SR) and extended-release (XL) were developed and approved by the FDA in 1996 and 2003, respectively (Fava et al., 2005; Stahl et al., 2004).”
BackgroundInfluentialWadden, T. A., Foreyt, J. P., Foster, G. D., Hill, J. O., Klein, S., O'Neil, P. M., Perri, M. G., Pi‐Sunyer, F. X., Rock, C. L., Erickson, J. S., et al. (2011) · Obesity · doi:10.1038/oby.2010.147 · Cited by 558
A clinical perspective of obesity, metabolic syndrome and cardiovascular disease
Han, T. S., & Lean, M. E. (2016) · JRSM Cardiovascular Disease · doi:10.1177/2048004016633371 · Cited by 500
Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations
Jefferson, J. W., Pradko, J. F., & Muir, K. T. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.11.011 · Cited by 408
Self-citationNutt, D., Demyttenaere, K., Janka, Z., Aarre, T., Bourin, M., Canonico, P. L., Carrasco, J. L., & Stahl, S. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881106069938 · Cited by 366
Self-citationBupropion: pharmacology and therapeutic applications
Foley, K. F., DeSanty, K. P., & Kast, R. E. (2006) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.6.9.1249 · Cited by 352
International Journal of Collaborative Research on Internal Medicine & Public Health
Valdivia, J. R. M. (2021) · Journal of Womens Health Issues and Care · Cited by 300
Matt, S. M., & Gaskill, P. J. (2020) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-019-09851-4 · Cited by 287
“These effects could also be induced by therapeutic agents that increase dopamine or act on DRs, such as Bromocriptine, L-DOPA, Emsam or Wellbutrin (Brannan et al. 1993; Lamensdorf et al. 1999; Stahl et al. 2004).”
Schultz, M. M., & Furlong, E. T. (2008) · Analytical Chemistry · doi:10.1021/ac702154e · Cited by 279
15 Years of Clinical Experience With Bupropion HCl: From Bupropion to Bupropion SR to Bupropion XL
Fava, M., Rush, A. J., Thase, M. E., Clayton, A., Stahl, S. M., Pradko, J. F., & Johnston, J. A. (2005) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v07n0305 · Cited by 258
“Bupropion is the only new generation antidepressant available in the United States with no appreciable serotonergic activity.(9,10,12,13) Bupropion appears to enhance monoaminergic neurotransmission via its effects on both the NE and DA transporters, with subsequent reuptake inhibition of these 2 neurotransmitters.”
BackgroundResultSelf-citationHypoactive Sexual Desire Disorder
Goldstein, I., Kim, N. N., Clayton, A. H., DeRogatis, L. R., Giraldi, A., Parish, S. J., Pfaus, J., Simon, J. A., Kingsberg, S. A., Meston, C., et al. (2017) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2016.09.018 · Cited by 230
Self-citationAnhedonia and Substance Dependence: Clinical Correlates and Treatment Options
Hatzigiakoumis, D. S., Martinotti, G., Giannantonio, M. D., & Janiri, L. (2011) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2011.00010 · Cited by 235
Bupropion for the treatment of methamphetamine dependence
Elkashef, A. M., Rawson, R. A., Anderson, A. L., Li, S.-H., Holmes, T., Smith, E. V., Chiang, N., Kahn, R., Vocci, F., Ling, W., et al. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301481 · Cited by 234
“…ae8a@nih.gov Neuropsychopharmacology (2008) 33, 1162–1170 & 2008 Nature Publishing Group All rights reserved 0893-133X/08 $30.00 www.neuropsychopharmacology.org can occupy the dopamine (DA) transporter to inhibit reuptake and increase DA concentration in the synaptic cleft (Stahl et al, 2004).”
BackgroundInfluentialInnovative approaches for the development of antidepressant drugs: Current and future strategies
Schechter, L. E., Ring, R. H., Beyer, C. E., Hughes, Z. A., Khawaja, X., Malberg, J. E., & Rosenzweig-Lipson, S. (2005) · NeuroRX · doi:10.1602/neurorx.2.4.590 · Cited by 228
“Bupropion (Wellbutrin), likely by virtue of its ability to block the reuptake of norepinephrine and dopamine, has been touted as an effective antidepressant with less incidence of side effects including sexual dysfunction and weight gain.(8) Notably and regardless of their mechanism of action, there continue to be sig…”
BackgroundStrategies for managing sexual dysfunction induced by antidepressant medication
Taylor, M. J., Rudkin, L., Bullemor-Day, P., Lubin, J., Chukwujekwu, C., & Hawton, K. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003382.pub3 · Cited by 225
Antidepressant therapies inhibit inflammation and microglial M1-polarization
Kalkman, H. O., & Feuerbach, D. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.04.001 · Cited by 212
Bupropion: a systematic review and meta-analysis of effectiveness as an antidepressant
Patel, K., Allen, S., Haque, M. N., Angelescu, I., Baumeister, D., & Tracy, D. K. (2016) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125316629071 · Cited by 194
“It has no effects on serotonin, histamine, acetylcholine or adrenaline (epinephrine) receptors; it is thus not associated with significant sedation, cognitive or anticholinergic gastrointestinal or hypotensive side effects [Stahl et al. 2004].”
BackgroundBrustolim, D., Ribeiro-dos-Santos, R., Kast, R. E., Altschuler, E. L., & Soares, M. B. P. (2006) · International Immunopharmacology · doi:10.1016/j.intimp.2005.12.007 · Cited by 194
“Bupropion increases extracellular amounts of norepinephrine and dopamine by inhibiting their transport back into the cell after release [7].”
BackgroundWilens, T. E., Haight, B. R., Horrigan, J. P., Hudziak, J. J., Rosenthal, N. E., Connor, D. F., Hampton, K. D., Richard, N. E., & Modell, J. G. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.01.027 · Cited by 193
Self-citationExtended-release bupropion: an antidepressant with a broad spectrum of therapeutic activity?
Clayton, A. H. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.4.457 · Cited by 186
“Bupropion is thought to act via dual inhibition of noradrenaline and dopamine re-uptake (NDRI), and is devoid of clinically significant serotonergic effects [4].”
BackgroundBupropion Reduces Methamphetamine-Induced Subjective Effects and Cue-Induced Craving
Newton, T. F., Roache, J. D., De La Garza, R., Fong, T., Wallace, C. L., Li, S.-H., Elkashef, A., Chiang, N., & Kahn, R. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300979 · Cited by 164
“Bupropion is an antidepressant with stimulant properties (Stahl et al, 2004) that is effective for the treatment of nicotine dependence (Richmond and Zwar, 2003).”
BackgroundTreatment of anxiety and depression: medicinal plants in retrospect
Fajemiroye, J. O., da Silva, D. M., de Oliveira, D. R., & Costa, É. A. (2016) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12186 · Cited by 177
Pathophysiology and Current Drug Treatments for Post-Stroke Depression: A Review
Frank, D., Gruenbaum, B. F., Zlotnik, A. A., Semyonov, M., Frenkel, A., & Boyko, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315114 · Cited by 174
“They perform their intended function by preventing the reabsorption of norepinephrine and dopamine into the brain [88].”
BackgroundInfluentialKolla, B. P., Mansukhani, M. P., & Bostwick, J. M. (2017) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2017.06.002 · Cited by 153
Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence
SHOPTAW, S. J., Heinzerling, K. G., Rotheram-Fuller, E. J., Steward, T., Wang, J., Swanson, A., Garza, R. D. L., Newton, T., & Ling, W. W. (2008) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2008.03.010 · Cited by 169
“Bupropion has relatively few antidepressant-associated side effects, such as sexual dysfunction and sedation (Stahl et al., 2004), has a low abuse potential (Nomikos et al., 1989), and is not fatal when taken in large doses (Shepherd et al., 2004).”
BackgroundComparative study of the effects of bupropion and escitalopram on I nternet gaming disorder
Song, J., Park, J. H., Han, D. H., Roh, S., Son, J. H., Choi, T. Y., Lee, H., Kim, T. H., & Lee, Y. S. (2016) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12429 · Cited by 157
“Bupropion’s mechanism of action is to inhibit the reuptake of both dopamine and norepinephrine.(7,9) In addition to its antidepressant effects, bupropion has anti-craving and anti-withdrawal activity that makes it an effective smoking-cessation aid by inhibiting dopamine reuptake.”
BackgroundAn overview on neurobiology and therapeutics of attention-deficit/hyperactivity disorder
da Silva, B. S., Grevet, E. H., Silva, L. C. F., Ramos, J. K. N., Rovaris, D. L., & Bau, C. H. D. (2023) · Discover Mental Health · doi:10.1007/s44192-022-00030-1 · Cited by 163
Bupropion: A Review of its Use in the Management of Major Depressive Disorder
Dhillon, S., Yang, L. P. H., & Curran, M. P. (2008) · Drugs · doi:10.2165/00003495-200868050-00011 · Cited by 156
Norepinephine transporter inhibitors and their therapeutic potential
Zhou, J. (2004) · Drugs of the Future · doi:10.1358/dof.2004.029.12.855246 · Cited by 164
“Einarson TR, Addis A, Mittmann N, Iskedjian M. Meta-analysis of venlafaxine, SSRIs and TCAs in the treatment of major depressive disorder.”
BackgroundInfluentialUse of Bupropion in Combination with Serotonin Reuptake Inhibitors
Zisook, S., Rush, A. J., Haight, B. R., Clines, D. C., & Rockett, C. B. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.06.027 · Cited by 173
Self-citationOral selective serotonin reuptake inhibitors activate vagus nerve dependent gut-brain signalling
Neufeld, K. M., Bienenstock, J., Bharwani, A., Champagne-Jorgensen, K., Mao, Y., West, C. L., Liu, Y., Surette, M. G., Kunze, W., & Forsythe, P. (2019) · Scientific Reports · doi:10.1038/s41598-019-50807-8 · Cited by 150
Cardiometabolic effects of psychotropic medications
Abosi, O. J., Lopes, S., Schmitz, S. L., & Fiedorowicz, J. G. (2018) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2017-0065 · Cited by 156
“Bupropion has no effect on adrenergic, histamine or serotonergic receptors [50].”
Review: Bupropion and SSRI-induced side effects
Demyttenaere, K., & Jaspers, L. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107083798 · Cited by 145
CYP2B6 Genotype Alters Abstinence Rates in a Bupropion Smoking Cessation Trial
Lee, A. M., Jepson, C., Hoffmann, E. B., Epstein, L. H., Hawk, L. W., Lerman, C. E., & Tyndale, R. F. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.10.005 · Cited by 139
Seasonal Affective Disorder and Its Prevention by Anticipatory Treatment with Bupropion XL
Modell, J. G., Rosenthal, N. E., Harriett, A. E., Krishen, A., Asgharian, A., Foster, V. J., Metz, A. L., Rockett, C. B., & Wightman, D. S. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.07.021 · Cited by 139
Self-citationKingsberg, S. A., Clayton, A. H., & Pfaus, J. G. (2015) · CNS Drugs · doi:10.1007/s40263-015-0288-1 · Cited by 133
Peciña, M., Sikora, M., Avery, E. T., Heffernan, J., Peciña, S., Mickey, B. J., & Zubieta, J.-K. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2017.08.427 · Cited by 131
“…of DA signaling with DA agonists, such as bromocriptine or pramipexole (Bouras and Bridges, 1982; Cassano et al., 2005; Shopsin and Gershon, 1978) and DA transporter (DAT) inhibitors, such as amineptine and bupropion, exhibit varying degrees of antidepressant effects (Stahl et al., 2004).”
Behlke, L. M., Lenze, E. J., & Carney, R. M. (2020) · CNS Drugs · doi:10.1007/s40263-020-00763-z · Cited by 135
The molecular pathophysiology of depression and the new therapeutics
Tian, H., Hu, Z., Xu, J., & Wang, C. (2022) · MedComm · doi:10.1002/mco2.156 · Cited by 122
An updated review on synthetic cathinones
Soares, J., Costa, V. M., Bastos, M. D. L., Carvalho, F. D., & Capela, J. P. (2021) · Archives of Toxicology · doi:10.1007/s00204-021-03083-3 · Cited by 122
Zajecka, J., Schatzberg, A. F., Stahl, S. M., Shah, A., Caputo, A., & Post, A. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181d420a7 · Cited by 117
“Currently available effective antidepressants are selective serotonin reuptake inhibitors (SSRIs), serotoninnorepinephrine reuptake inhibitors (SNRIs), norepinephrine and dopamine reuptake inhibitors (NDRIs), dual action antidepressants (eg, mirtazapine, nefadozone), tricyclic antidepressants (TCAs), and monoamine oxi…”
BackgroundSelf-citationFigueroa, R. (2010) · Journal of Developmental & Behavioral Pediatrics · doi:10.1097/dbp.0b013e3181e5ac93 · Cited by 116
Approaches to the development of medications for the treatment of methamphetamine dependence
Vocci, F. J., & Appel, N. M. (2007) · Addiction · doi:10.1111/j.1360-0443.2007.01772.x · Cited by 121
Emotion-based decision-making in healthy subjects: short-term effects of reducing dopamine levels
Sevy, S. M., Hassoun, Y., Bechara, A., Yechiam, E., Napolitano, B. A., Burdick, K. E., Delman, H., & Malhotra, A. K. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0450-z · Cited by 126
“Bupropion, a smoking cessation aid, is a dopamine reuptake inhibitor (Stahl et al. 2004).”
BackgroundThe Druggability of Solute Carriers
Wang, W., Gallo, L. H., Jadhav, A. M., Hawkins, R., & Parker, C. G. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01237 · Cited by 115
Martino, M., Rocchi, G., Escelsior, A., & Fornaro, M. (2012) · Current Neuropharmacology · doi:10.2174/157015912800604542 · Cited by 111
“Bupropion with its metabolites inhibits reuptake for human transporters for both DA and NE, with slightly greater functional potency at DA transporter than at NE transporter, increasing DA and NE concentrations in prefrontal cortex and DA concentrations in nucleus accumbens [338].”
BackgroundAbuse and misuse of antidepressants
Sullivan, M. A., & Evans, E. (2014) · Substance Abuse and Rehabilitation · doi:10.2147/sar.s37917 · Cited by 118
“51,52 Theoretically, given its noradrenergic and dopaminergic effects, bupropion may promote regulation of function in mesolimbic brain circuits, an important system in the activating and reinforcing effects of indirect sympathomimetics (eg, cocaine, methamphetamine, nicotine).”
Schifano, F., Chiappini, S., Corkery, J., & Guirguis, A. (2018) · Brain Sciences · doi:10.3390/brainsci8040073 · Cited by 111
“Bupropion pharmacology relies on its action both as a selective inhibitor of catecholamines (noradrenaline and DA) reuptake [35,36], and as a non-competitive antagonist of nicotinic acetylcholine receptors, hence being prescribed as well as an aid in smoking cessation [36].”
BackgroundPedersen, L. H., Nielsen, A. N., & Blackburn-Munro, G. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0120-6 · Cited by 103
“Bupropion is a selective NA and DA re-uptake inhibitor with no serotonergic activity (Stahl et al. 2004).”
BackgroundLittle, J. T., Ketter, T. A., Kimbrell, T. A., Dunn, R. T., Benson, B. E., Willis, M. W., Luckenbaugh, D. A., & Post, R. M. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.10.033 · Cited by 104
Sexual Function during Bupropion or Paroxetine Treatment of Major Depressive Disorder
Kennedy, S. H., Fulton, K., Bagby, R. M., Greene, A. L., Cohen, N. L., & Rafi‐Tari, S. (2006) · The Canadian Journal of Psychiatry · doi:10.1177/070674370605100405 · Cited by 95
“Conversely, bupropion, with a novel mechanism of action involving dual inhibition of norepinephrine and dopamine reuptake, is devoid of any direct effects on the serotonin system (25).”
BackgroundThase, M. E., Clayton, A. H., Haight, B. R., Thompson, A. H., Modell, J. G., & Johnston, J. A. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000239790.83707.ab · Cited by 93
“These drugs are thought to work through different mechanisms of action; bupropion is a norepinephrinedopamine reuptake inhibitor and venlafaxine is a serotoninnorepinephrine reuptake inhibitor (SNRI).(2,3) Although a small single-blind randomized crossover study comparing bupropion and venlafaxine was recently reporte…”
BackgroundSelf-citationIncidence and onset of delayed seizures after overdoses of extended-release bupropion
Starr, P. E., Klein‐Schwartz, W., Spiller, H. A., Kern, P., Ekleberry, S. E., & Kunkel, S. J. (2009) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2008.07.004 · Cited by 91
“It is not known to interfere with serotonin reuptake or inhibit monoamine oxidase [2,4].”
BackgroundSevvanthi, S., Muthu, S., & Raja, M. (2018) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2018.07.001 · Cited by 84
Effect of Bupropion Treatment on Brain Activation Induced by Cigarette-Related Cues in Smokers
Culbertson, C. S., Bramen, J. E., Cohen, M. S., London, E. D., Olmstead, R. E., Gan, J. J., Costello, M. R., Shulenberger, S., Mandelkern, M. A., & Brody, A. L. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.193 · Cited by 90
“Bupropion and its metabolites appear to modulate smoking-induced dopamine release by increasing extracellular dopamine and norepinephrine levels in subcortical regions (striatum and locus coeruleus, respectively) through the inhibition of dopamine and norepinephrine reuptake transporters.(16-24) Enhancing subcortical…”
BackgroundSilins, E., Copeland, J., & Dillon, P. (2007) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/00048670701449237 · Cited by 81
“of clinically significant serotonergic effects [39], and therefore 650 SEROTONIN SYNDROME AND MDMA”
BackgroundSafarinejad, M. R. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881109351966 · Cited by 80
“Bupropion has relatively few antidepressantassociated side effects, such as sexual dysfunction (Stahl et al., 2004).”
BackgroundThe ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder
(2024) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001299 · Cited by 78
Treatment of Maternal Depression in a Medication Clinical Trial and Its Effect on Children
Weissman, M. M., WICKRAMARATNE, P. J., Pilowsky, D. J., Poh, E., Batten, L. A., Hernández, M., Flament, M. F., Stewart, J. A., McGrath, P. J., Blier, P., et al. (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2014.13121679 · Cited by 88
Sexual Health after a Breast Cancer Diagnosis: Addressing a Forgotten Aspect of Survivorship
Vegunta, S., Kuhle, C. L., Vencill, J. A., Lucas, P. H., & Mussallem, D. M. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11226723 · Cited by 77
Tsoi, D. T.-Y., Porwal, M., & Webster, A. C. (2010) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.109.066019 · Cited by 83
“10 Research suggests that bupropion acts as a non-competitive antagonist at the nicotinic acetycholinergic receptor.”
Arias, H. R. (2009) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2009.05.015 · Cited by 76
Fatigue as a core symptom in major depressive disorder: overview and the role of bupropion
Pae, C., Lim, H. K., Han, C., Patkar, A. A., Steffens, D. C., Masand, P. S., & Lee, C. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.10.1251 · Cited by 80
Glutamatergic Modulators for Major Depression from Theory to Clinical Use
McIntyre, R. S., & Jain, R. (2024) · CNS Drugs · doi:10.1007/s40263-024-01114-y · Cited by 69
“In addition to serving as metabolic inhibitor of cytochrome P450 2D6 [21], bupropion enhances monoaminergic function as a norepinephrine–dopamine reuptake inhibitor and is approved to treat MDD (target dose 300 mg/day, maximum dose 450 mg/day) [136, 137].”
BackgroundEvaluation of electrochemical methods for tonic dopamine detection in vivo
Rusheen, A. E., Gee, T. A., Jang, D. P., Blaha, C. D., Bennet, K. E., Lee, K. H., Heien, M. L., & Oh, Y. (2020) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2020.116049 · Cited by 70
Bupropion and Bupropion Analogs as Treatments for CNS Disorders
Carroll, F. I., Blough, B. E., Mascarella, S. W., Navarro, H. A., Lukas, R. J., & Damaj, M. I. (2014) · Advances in pharmacology · doi:10.1016/b978-0-12-420118-7.00005-6 · Cited by 75
The Role of the Habenula in Nicotine Addiction
Baldwin, P. R., Alanis, R., & Salas, R. (2012) · Journal of Addiction Research & Therapy · doi:10.4172/2155-6105.s1-002 · Cited by 74
“Bupropion acts mainly at three molecules: it blocks the reuptake of dopamine and norepinephrine, which can account for its antidepressant effects [77], and is also a β4-containing nAChR antagonist [58].”
BackgroundBupropion attenuates nicotine abstinence syndrome in the rat
Malin, D. H., Lake, J. R., Smith, T. D., Khambati, H. N., Meyers-Paal, R. L., Montellano, A. L., Jennings, R. E., Erwin, D. S., Presley, S. E., & Perales, B. A. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0135-z · Cited by 67
“However, bupropion and most other antidepressants require chronic administration before achieving antidepressant effects (Stahl et al. 2004), while acute administration immediately attenuated nicotine abstinence syndrome in this study and that of Cryan et al. (2003).”
BackgroundMechanistic insights into nicotine withdrawal
Paolini, M., & De Biasi, M. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.07.075 · Cited by 66
Hewett, K., Gee, M., Krishen, A., Wunderlich, H.-P., Clus, A. L., Evoniuk, G. E., & Modell, J. G. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881109106953 · Cited by 66
“Bupropion, a dual noradrenaline and dopamine reuptake inhibitor (NDRI) (Stahl et al., 2004), has been shown to be effective and well tolerated in the treatment of depression (Coleman et al.”
BackgroundSelf-citationSafety of intravenous methamphetamine administration during treatment with bupropion
Newton, T. F., Roache, J. D., Garza, R. D. L., Fong, T., Wallace, C. L., Li, S.-H., Elkashef, A. M., Chiang, N., & Kahn, R. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0102-8 · Cited by 69
“Bupropion is an antidepressant with stimulant properties (Stahl et al. 2004) that is effective for the treatment of nicotine dependence (Richmond and Zwar 2003).”
Long-Term Weight Change after Initiating Second-Generation Antidepressants
Arterburn, D. E., Sofer, T., Boudreau, D. M., Bogart, A., Westbrook, E. O., Theis, M. K., Simon, G., & Haneuse, S. (2016) · Journal of Clinical Medicine · doi:10.3390/jcm5040048 · Cited by 68
Soczynska, J. K., Ravindran, L. N., Styra, R., McIntyre, R. S., Cyriac, A., Manierka, M. S., & Kennedy, S. H. (2014) · Psychiatry Research · doi:10.1016/j.psychres.2014.06.053 · Cited by 60
Nasrin, S., Islam, M. N., Tayab, M. A., Nasrin, S., Siddique, M. A. B., Emran, T. B., & Reza, A. S. M. A. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112842 · Cited by 62
Alberti, S., Chiesa, A., Andrisano, C., & Serretti, A. (2015) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000329 · Cited by 65
Bourin, M., Chenu, F., Prica, C., & Hascoët, M. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1583-7 · Cited by 59
Billes, S. K., & Cowley, M. A. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301155 · Cited by 63
The new era of drug therapy for obesity: the evidence and the expectations
Jones, B. J., & Bloom, S. R. (2015) · Drugs · doi:10.1007/s40265-015-0410-1 · Cited by 58
“Bupropion, an aminoketone which acts as a mixed dopamine/ norepinephrine reuptake inhibitor [60], is used as an antidepressant and in smoking cession, and has previously been evaluated as monotherapy in the treatment of obesity [61].”
Pharmacotherapy of obesity: An update
Cignarella, A., Busetto, L., & Vettor, R. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105649 · Cited by 65
Hewett, K., Chrzanowski, W., Schmitz, M., Savela, A., Milanova, V, Gee, M., Krishen, A., Millen, L., Leary, M., & Modell, J. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881108089602 · Cited by 57
Self-citationDysphoric milk ejection reflex: A case report
Heise, A. M., & Wiessinger, D. (2011) · International Breastfeeding Journal · doi:10.1186/1746-4358-6-6 · Cited by 61
“Bupropion - 150 mg/day ↑ [21] 0? improved No literature found on the effect of bupropion on oxytocin release.”
BackgroundBreuer, M. E., Chan, J. S. W., Oosting, R. S., Groenink, L., Korte, S. M., Campbell, U. C., Schreiber, R., Hanania, T., Snoeren, E. M. S., Waldinger, M. D., et al. (2008) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2008.07.011 · Cited by 60
“, 2004) is suggested to be without sexual side effects (Stahl et al., 2004; Foley et al., 2006) and is often prescribed as co-medication with SSRIs to counteract sexual side effects (Clayton et al.”
BackgroundHewett, K., Chrzanowski, W., Jokinen, R., Felgentreff, R., Rk, S., Gee, M., Wightman, D., O'Leary, M., Millen, L., Leon, M., et al. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881108100254 · Cited by 60
Self-citationChoi, J., Cho, H., Kim, J.-Y., Jung, D. J., Ahn, K. J., Kang, H.-B., Choi, J., Chun, J., & Kim, D. (2017) · Scientific Reports · doi:10.1038/s41598-017-01275-5 · Cited by 60
Antidepressant drugs and memory: Insights from animal studies
Monleón, S., Vinader‐Caerols, C., Arenas, M. C., & Parra, A. (2007) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2007.07.001 · Cited by 61
“Bupropion acts through a dual inhibition of norepinephrine and dopamine reuptake, and has no clinically significant serotonergic effects or direct effects on postsynaptic receptors (Stahl et al., 2004).”
BackgroundInfluentialModulation of neuroimmune cytokine networks by antidepressants: implications in mood regulation
Nava, R. G., Adri, A. S., Filgueiras, I. S., Nóbile, A. L., Barcelos, P. M., Corrêa, Y. L. G., de Oliveira, S. F., Cabral‐Miranda, G., Dias, H. D., Schimke, L. F., et al. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03532-y · Cited by 57
“Notably, the impact on 5-HT reuptake is minimal [136].”
Dopamine activates NF-κB and primes the NLRP3 inflammasome in primary human macrophages
Nolan, R. A., Reeb, K. L., Rong, Y., Matt, S. M., Johnson, H. S., Runner, K., & Gaskill, P. J. (2019) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2019.100030 · Cited by 62
“These effects might also be mediated by therapeutic agents that increase dopamine or act on dopamine receptors, such as Bromocriptine, L-DOPA, Emsam or Wellbutrin (Brannan et al., 1993; Lamensdorf et al., 1999; Stahl et al., 2004).”
BackgroundShoptaw, S., Heinzerling, K. G., Rotheram-Fuller, E., Kao, U. H., Wang, P.-C., Bholat, M. A., & Ling, W. (2008) · Journal of Addictive Diseases · doi:10.1300/j069v27n01_02 · Cited by 54
Baghai, T. C., Volz, H., & Möller, H. (2006) · The World Journal of Biological Psychiatry · doi:10.1080/15622970601003973 · Cited by 59
“The compound enhances monoaminergic neurotransmission due to its effects on noradrenaline and dopamine reuptake inhibition (Asher et al. 1995; Stahl et al. 2004), therefore some researchers define the compound as a dopamine/noradrenaline reuptake inhibitor (DNRI).”
BackgroundRisk Factors, Clinical Consequences, Prevention, and Treatment of Childhood Obesity
Shaban Mohamed, M. A., AbouKhatwa, M. M., Saifullah, A. A., Hareez Syahmi, M., Mosaad, M., Elrggal, M. E., Dehele, I. S., & Elnaem, M. H. (2022) · Children · doi:10.3390/children9121975 · Cited by 52
“Bupropion is a dopamine/norepinephrine reuptake inhibitor approved to be used in depression and aids in smoking cessation [104].”
BackgroundReceptor targets for antidepressant therapy in bipolar disorder: An overview
Fountoulakis, K. Ν., Kelsoe, J. R., & Akiskal, H. S. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.04.043 · Cited by 54
Safarinejad, M. R. (2010) · British Journal of Urology · doi:10.1111/j.1464-410x.2009.09154.x · Cited by 51
RetractedInteractions between Bupropion and 3,4-Methylenedioxymethamphetamine in Healthy Subjects
Schmid, Y., Rickli, A., Schaffner, A., Duthaler, U., Grouzmann, E., Hysek, C. M., & Liechti, M. E. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.222356 · Cited by 51
“Bupropion reaches a high brain-to-plasma ratio and brain concentrations above its IC50 value for DA transporter inhibition (Stahl et al., 2004).”
BackgroundInfluentialEap, C. B., Gründer, G., Baumann, P., Ansermot, N., Conca, A., Corruble, E., Crettol, S., Dahl, M., de León, J., Greiner, C., et al. (2021) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2021.1878427 · Cited by 57
The Efficacy and Tolerability of Bupropion in the Treatment of Major Depressive Disorder
Moreira, R. (2011) · Clinical Drug Investigation · doi:10.2165/1159616-s0-000000000-00000 · Cited by 55
“Bupropion is devoid of serotenergic activity([21]) and does not affect MAO nor interact with histaminic, cholinergic or a1-adrenoceptors.”
Metabolism of Bupropion by Carbonyl Reductases in Liver and Intestine
Connarn, J. N., Zhang, X., Babiskin, A. H., & Sun, D. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.063107 · Cited by 52
“Bupropion is a norepinephrine/dopamine reuptake inhibitor (Stahl et al., 2004) clinically used for treatment of major depressive disorder (MDD) and smoking cessation (Fava et al.”
Antidepressant and Antipsychotic Drugs
Krystal, A. D. (2010) · Sleep Medicine Clinics · doi:10.1016/j.jsmc.2010.08.010 · Cited by 50
Covey, L. S., Glassman, A. H., Jiang, H., Fried, J., Masmela, J. R., LoDuca, C., Petkova, E., & Rodriguez, K. (2007) · Addiction · doi:10.1111/j.1360-0443.2007.01887.x · Cited by 54
Metadata
- Authors
- Stahl, S. M., Pradko, J., Haight, B. R., Modell, J. G., Rockett, C. B., & Learned-Coughlin, S.
- Affiliations
- University of California San Diego (US)
- St. John Hospital & Medical Center (US)
- Corresponding author
- Modell, Jack G.
- ORCID
- Stahl, Stephen M.
- Venue
- The Primary Care Companion For CNS Disorders
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2004-08-13
- Volume
- 6
- Issue
- 4
- Pages
- 159-166
- ISSN
- 2155-7772 (ISSN-L)
- 2155-7780
- PMC
- PMC514842
- OpenAlex
- W2046809238
- Cited by
- 495
- References
- 92
- Citations by year
- 2026: 14 · 2025: 28 · 2024: 31 · 2023: 33 · 2022: 35 · 2021: 27 · 2020: 27 · 2019: 19 · 2018: 36 · 2017: 25 · 2016: 29 · 2015: 23 · 2014: 19 · 2013: 20 · 2012: 15
- FWCI
- 8.57
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Primary Care Companion For CNS Disorders (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- bupropion, norepinephrine reuptake inhibition, dopamine uptake inhibition, antidepressant mechanism, antidepressant efficacy, antidepressant tolerability, sexual dysfunction, weight gain, sedation, serotonergic effects
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.